Home | Contact us | Disclaimer


Lilly has assumed all development and commercialization rights to type 2 diabetes drug candidate TT401. If TT-401 is successfully commercialized, Transition will be eligible to receive approximately US$240 million in additional milestone payments. Transition will also be eligible to receive a double-digit royalty on sales of TT401 products and a low single digit royalty on related compounds.
© 2013 Transition Therapeutics Inc.